Paolo Cassano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7288381/publications.pdf

Version: 2024-02-01

40 papers	1,904 citations	361296 20 h-index	289141 40 g-index
42 all docs	42 docs citations	42 times ranked	2285 citing authors

#	Article	IF	Citations
1	Transcranial Photobiomodulation in Adults with High-Functioning Autism Spectrum Disorder: Positive Findings from a Proof-of-Concept Study. Photobiomodulation, Photomedicine, and Laser Surgery, 2022, 40, 4-12.	0.7	10
2	Transcranial Photobiomodulation Therapy for Sexual Dysfunction Associated with Depression or Induced by Antidepressant Medications. Photonics, 2022, 9, 330.	0.9	3
3	Pilot Study on Dose-Dependent Effects of Transcranial Photobiomodulation on Brain Electrical Oscillations: A Potential Therapeutic Target in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 1481-1498.	1.2	18
4	Dosimetry and Clinical Efficacy of Transcranial Photobiomodulation for Major Depression Disorder: Could they Guide Dosimetry for Alzheimerâ€™s Disease?. Journal of Alzheimer's Disease, 2021, 83, 1453-1469.	1.2	10
5	Randomized, Placebo-Controlled Trial of the Angiotensin Receptor Antagonist Losartan for Posttraumatic Stress Disorder. Biological Psychiatry, 2021, 90, 473-481.	0.7	21
6	Transitioning From In-Person to Remote Clinical Research on Depression and Traumatic Brain Injury During the COVID-19 Pandemic: Study Modifications and Preliminary Feasibility From a Randomized Controlled Pilot Study. JMIR Formative Research, 2021, 5, e28734.	0.7	6
7	Treatment of Kleine-Levin Syndrome With Intranasal Photobiomodulation and Methylene Blue. Cureus, 2021, 13, e18596.	0.2	2
8	Therapeutic potential of intranasal photobiomodulation therapy for neurological and neuropsychiatric disorders: a narrative review. Reviews in the Neurosciences, 2020, 31, 269-286.	1.4	40
9	Transcranial photobiomodulation with near-infrared light from childhood to elderliness: simulation of dosimetry. Neurophotonics, 2020, 7, 1.	1.7	22
10	Reported Side Effects, Weight and Blood Pressure, After Repeated Sessions of Transcranial Photobiomodulation. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 651-656.	0.7	28
11	Transcranial Photobiomodulation Improves Cognitive Performance in Young Healthy Adults: A Systematic Review and Meta-Analysis. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 635-643.	0.7	23
12	Penetration Profiles of Visible and Near-Infrared Lasers and Light-Emitting Diode Light Through the Head Tissues in Animal and Human Species: A Review of Literature. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 581-595.	0.7	84
13	Transcranial Photobiomodulation with Near-Infrared Light for Generalized Anxiety Disorder: A Pilot Study. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 644-650.	0.7	24
14	Transcranial Photobiomodulation for Down Syndrome. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 579-580.	0.7	3
15	Transcranial Photobiomodulation to Augment Lithium in Bipolar-I Disorder. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 577-578.	0.7	8
16	Photomedicine and Pharmaceuticals: A Brain New Deal. Photobiomodulation, Photomedicine, and Laser Surgery, 2019, 37, 575-576.	0.7	2
17	Effects of transcranial photobiomodulation with nearâ€infrared light on sexual dysfunction. Lasers in Surgery and Medicine, 2019, 51, 127-135.	1.1	18
18	Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms. Journal of Affective Disorders, 2019, 243, 262-273.	2.0	72

#	Article	IF	Citations
19	Near-infrared photobiomodulation combined with coenzyme Q10 for depression in a mouse model of restraint stress: reduction in oxidative stress, neuroinflammation, and apoptosis. Brain Research Bulletin, 2019, 144, 213-222.	1.4	87
20	Selective photobiomodulation for emotion regulation: model-based dosimetry study. Neurophotonics, 2019, 6, 1.	1.7	49
21	Prospective association between major depressive disorder and leukocyte telomere length over two years. Psychoneuroendocrinology, 2018, 90, 157-164.	1.3	32
22	A case control series for the effect of photobiomodulation in patients with low back pain and concurrent depression. Laser Therapy, 2018, 27, 167-173.	0.8	13
23	A Protocol for Transcranial Photobiomodulation Therapy in Mice. Journal of Visualized Experiments, 2018, , .	0.2	12
24	Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial. Photomedicine and Laser Surgery, 2018, 36, 634-646.	2.1	73
25	Sex Differences in the Association between Heavy Drinking and Behavioral Distress Tolerance and Emotional Reactivity Among Non-Depressed College Students. Alcohol and Alcoholism, 2018, 53, 674-681.	0.9	8
26	Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation. Australian and New Zealand Journal of Psychiatry, 2017, 51, 55-64.	1.3	84
27	Inflammatory cytokines in major depressive disorder: A caseâ€“control study. Australian and New Zealand Journal of Psychiatry, 2017, 51, 23-31.	1.3	60
28	Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. Neurophotonics, 2016, 3, 031404.	1.7	136
29	Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine. Journal of Clinical Psychiatry, 2016, 77, e719-e725.	1.1	100
30	Major depressive disorder with psychosis-like symptoms in Latinos: treatment with and without antipsychotic augmentation. International Journal of Culture and Mental Health, 2015, 8, 137-149.	0.6	1
31	Treatment Outcome in Depressed Latinos Predicted by Concomitant Psychosislike Symptoms. Journal of Nervous and Mental Disease, 2015, 203, 769-773.	0.5	1
32	Treatments for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy. Neuropsychiatric Disease and Treatment, 2015, 11, 2159.	1.0	108
33	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry Journal, 2015, 2015, 1-8.	0.7	90
34	In Latinos with major depressive disorder, do â€˜soft psychoticâ€™ symptoms merit augmentation with atypical antipsychotics?. International Journal of Culture and Mental Health, 2014, 7, 370-371.	0.6	1
35	Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos. Journal of Affective Disorders, 2013, 150, 578-584.	2.0	14
36	Major Depressive Disorder With Psychosis-Like Symptoms Among Latinos. Psychiatric Services, 2012, 63, 482-487.	1.1	11

#	Article	IF	Citations
37	Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study. Canadian Journal of Psychiatry, 2005, 50, 357-360.	0.9	62
38	Antidepressant Response and Well-Being in Pre-, Peri- and Postmenopausal Women with Major Depressive Disorder Treated with Fluoxetine. Psychotherapy and Psychosomatics, 2005, 74, 362-365.	4.0	19
39	Tolerability Issues During Long-Term Treatment with Antidepressants. Annals of Clinical Psychiatry, 2004, 16, 15-25.	0.6	128
40	Depression and public health. Journal of Psychosomatic Research, 2002, 53, 849-857.	1.2	420